Investors
We are committed to delivering our strategy and creating value for our shareholders.
Latest News
Latest Events
Update on AGM Procedure
LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides an update on its upcoming Annual
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now demonstrated positive efficacy and safety in COPD patients via three widely used inhalation modes: nebulizer, DPI and pMDI Initiation of multiple dose part of pMDI trial postponed due to the
Verona Pharma plc: Issue of Equity and Total Voting Rights
LONDON, March 20, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it yesterday issued 887,080 Ordinary Shares of 5
Discover More
Verona Pharma
Investor Information
© Verona Pharma plc 2020. All rights reserved